linjc16/ctgov huggingface dataset:
Efficacy of Unstable Shoes for Instability and Lumbopelvic Pain

Study Overview
=================
Brief Summary
-----------------
During pregnancy, pregnant women adopt an atypical pattern position with the intention to maintain stability and balance.These postural changes can cause instability at the level of the sacroiliac joint with painful condition during pregnancy and postpartum. 40 % of women have postpartum lumbopelvic instability. In 17 % of cases the lumbopelvic pain is perpetuated. Another alteration influenced by the gestational status and progress of labor is urinary incontinence (UI). The mechanism developed by Masai Barefoot Technology (MBT) provides an unstable base. Some studies reviewed, indicate that this shoe increases muscle activity, contributes to the decrease of joint overload and thereby, decreases pain. Objective To compare the efficacy of shoes with unstable sole MBT®, over the use of conventional sports shoes, in primiparous women with lumbopelvic postpartum pain. Material and Methods Randomized clinical trial. 24 postpartum women from the Gynecology Service of the Hospital Universitario Madrid Chiron were included in the study. The subjects were randomly divided into experimental and control group.

Official Title
-----------------
Efficacy of Masai Barefoot Technology (MBT) for Decreasing Pain and Improvement of Lumbopelvic Pain

Conditions
-----------------
Lumbopelvic Postpartum Pain

Intervention / Treatment
-----------------
* Other: Use unstable shoes Masai Barefoot Technology (MBT)
* Other: Use conventional sport shoes


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primparous women. Postpartum, between 8-12 weeks after the date of delivery. With lumbopelvic pain and positive diagnostic tests of sacroiliac pain Women with ambulation ability. Exclusion Criteria: Presence of vaginal prolapses. Be receiving another treatment for the alteration that concerns us, pharmacological or any other type of therapy. Neuromuscular alterations.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A group<br> | Other: Use unstable shoes Masai Barefoot Technology (MBT)<br>* Use of unstable shoes during 9 weeks, at least four hours per day.<br>|
| Experimental: B group<br> | Other: Use conventional sport shoes<br>* Use of conventional sport shoes during 9 weeks, at least four hours per day.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain | Sacroiliac pain provocation test. | 9th week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pelvic Stability | Podiatric Stabilometry. | 9th week |
START: Swiss Taxotere Alopecia Prevention Trial

Study Overview
=================
Brief Summary
-----------------
Primary objective: Rate of complete chemotherapy induced alopecia (WHO grade III or IV, physician grading) Secondary objective: Compliance to scalp cooling procedure Received number of cycles of chemotherapy in each subgroup Patient perception of scalp cooling procedure Side effects of scalp cooling systems

Official Title
-----------------
A Comparison of Different Scalp Cooling Systems for the Prevention of Chemotherapy Induced Alopecia

Conditions
-----------------
Neoplasms, Alopecia

Intervention / Treatment
-----------------
* Device: Paxman Cooling Machine
* Device: Cold Caps


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any solid tumor malignancy receiving docetaxel (Taxotere®) 1st line chemotherapy treatment with the exception of regimen containing concomitant anthracycline treatment; sequential anthracycline/docetaxel treatment is permitted. Performance Status ECOG <= 2 Absence of alopecia at inclusion Exclusion Criteria: Chemotherapy regimen including concomitant anthracycline treatment Raynaud's disease or phenomenon Cold agglutinin disease Cryoglobulinemia Cryofibrinogenemia Scalp metastasis Pregnancy or Lactation Preexisting alopecia of any grade; notably androgenetic alopecia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br> | Device: Paxman Cooling Machine<br>* Scalp cooling procedures<br>|
| Active Comparator: B<br> | Device: Cold Caps<br>* Scalp cooling procedures<br>|
| No Intervention: C<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Grade III or IV alopecia according to the WHO criteria |  | D1 of each cycle and D+21 after last cycle of chemotherapy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compliance to scalp cooling procedure |  | D1 of each cycle and D+21 after last cycle of chemotherapy | 
| Side effects of scalp cooling systems |  | D1 of each cycle and D+21 after last cycle of chemotherapy |
Soft and Hard Tissues Evaluation Around Immediately Placed New Implant Design

Study Overview
=================
Brief Summary
-----------------
patients were randomly divided into Maxi-Z plus dental implant group versus Maxi-Z implant group

Detailed Description
-----------------
after tooth extraction implants will be placed immediately and provisional restoration will be placed in both groups to detect the advantaged and drawbacks of newly designed Maxi-Z plus dental implant versus Maxi-Z dental implant

Official Title
-----------------
Soft and Hard Tissues Evaluation Around Immediately Placed New Implant Design: Randomised Clinical Study

Conditions
-----------------
Peri-implant Mucositis, Dental Implant Failed

Intervention / Treatment
-----------------
* Procedure: platform switching
* Procedure: platform amtching


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: good health unrestorable, periodontal healthy teeth Exclusion Criteria: systemic disease periodontal disease presence of abscess

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Maxi-Z plus dental implant
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Maxi-Z plus dental implant<br>platform switched dental implants | Procedure: platform switching<br>* reduced implant abutment interface<br>|
| Active Comparator: Maxi-Z dental implant<br>platform matched dental implants | Procedure: platform amtching<br>* matched implant abutment interface<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Implant mobility using Periotest M | Periotest M values range from (-8 to 0). high values represent loose implant, while osseointegrated implants showed low values | 12 months | 
| marginal bone level | measured in mm using X-ray | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pink estheic score | from 0-12. 0 means bad aesthetic of soft tissue. 12 means the ultimate aesthetics of soft tissue | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
platform switched implants, platform matched implants
Validation of PSFS in Carpal Tunnel Syndrome

Study Overview
=================
Brief Summary
-----------------
Validation of the Patient Specific Functional Scale in patients with carpal tunnel syndrome

Official Title
-----------------
Validation of the Patient-Specific Functional Survey in Patients With Carpal Tunnel

Conditions
-----------------
Carpal Tunnel Syndrome

Intervention / Treatment
-----------------
* Other: PSFS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of carpal tunnel syndrome Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort<br>patients with carpal tunnel syndrome | Other: PSFS<br>* Patients will complete the patient specific functional scale. no intervention being administered<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient Specific Functional Scale Scores | PSFS measures perceived function. Patients rate their ability to perform self-selected tasks on a 0-10 scale, with higher scores indicating higher ability. | 2 weeks after initial completion | 
| Patient Specific Functional Scale Scores | Patients rate their ability to perform self-selected tasks on a 0-10 scale, with higher scores indicating higher ability. | 6 weeks after surgery |
The Efficacy of Transarterial Chemoinfusion (TAI) Combine Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC)

Study Overview
=================
Brief Summary
-----------------
To evaluate the efiicacy of TAI combine SBRT in unresectable HCC

Official Title
-----------------
The Efficacy of Transarterial Chemoinfusion (TAI) Combine Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC): A Prospective, Single-armed, Stage II Clinical Trial

Conditions
-----------------
Hepatocellular Carcinoma

Intervention / Treatment
-----------------
* Combination Product: TAI combine SBRT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: older than 18 years old and younger than 75 years; ECOG PS≤1; proven advanced hepatocellular carcinoma according patological examination or EASL/AASLD diagnostic criteria; not previous treated for tumor; cannot accepted hepatectomy; the lab test could meet: neutrophil count≥2.0×109/L; hemoglobin≥100g/L; platelet count≥75×109/L; serum albumin≥35g/L; total bilirubin<2-times upper limit of normal; ALT<3-times upper limit of normal; AST<3-times upper limit of normal; serum creatine<1.5-times upper limit of normal; PT≤upper limit of normal plus 4 seconds; INR≤2.2; sign up consent. Exclusion Criteria: cannot tolerate TAI or SBRT; known history of other malignancy; be allergic to related drugs; underwent organ transplantation before; be treated before (interferon included); known history of HIV infection; known history of drug or alcohol abuse; have GI hemorrhage or cardiac/brain vascular events within 30 days; pregnancy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: treatment group<br>TAI combine SBRT | Combination Product: TAI combine SBRT<br>* TAI combine SBRT<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PFS | progression-free survival | From date of randomization until the date of progression, assessed up to 36 months | 
| ORR | objective response rate | From date of randomization until the date of death, assessed up to 36 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OS | overall survival | From date of randomization until the date of death from any cause, assessed up to 36 months | 
| DCR | disease control rate | From date of randomization until the date of death, assessed up to 36 months |
Identifcation of Biomarkers for Active Pulmonary Tuberculosis

Study Overview
=================
Brief Summary
-----------------
This experiment is designed to analyze the metabolites in body fluids from patients with active tuberculosis and latent tuberculosis infection also with health volunteer, then combine the metabolic product features with clinical characteristics, to develop a kind of metabolites targets to evaluate the progress in tuberculosis, thus provide a basis for further utilization of humoral metabolites in the diagnosis of tuberculosis.

Official Title
-----------------
Identifcation of Biomarkers for Active Pulmonary Tuberculosis Using a Metabolomics Approach: a Prospective Multicenter Study

Conditions
-----------------
Tuberculosis, Diagnosis

Intervention / Treatment
-----------------
* Other: with no intervention, Collect samples


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with active tuberculosis and latent tuberculosis infection Exclusion Criteria: have other serious health problems
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| active<br>patients with active tuberculosis | Other: with no intervention, Collect samples<br>* only with observation,there is no need to intervene<br>|
| latent<br>patients with latent tuberculosis infection | Other: with no intervention, Collect samples<br>* only with observation,there is no need to intervene<br>|
| negtive control<br>healthy volunteers | Other: with no intervention, Collect samples<br>* only with observation,there is no need to intervene<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| metabolic product | features up-regulated or down-regulated | 24 hours after sampling |
Prospective Identification and Validation of BRCANess Profile in Ovarian Epithelial Cancer

Study Overview
=================
Brief Summary
-----------------
This is an observational prospective study. Patients diagnosed with advanced epithelial ovarian cancer (stage IC or higher) since 2008 will be asked to participate in this study by signing an informed consent. Tumour samples will be reviewed to confirm the diagnosis and to select the best regions for tissue sampling to perform the following molecular studies: array-based Comparative Genomic Hybridization and Next Generation Sequencing. Detected mutations will be analysed by Sanger sequencing. FISH probes will be designed and tested on the samples.

Official Title
-----------------
Multicentric Project for the Prospective Identification and Validation of Molecular Alterations That Define the BRCANess Profile in Ovarian Epithelial Cancer and Its Application as a Response Predictor to Platinum and Antitarget Therapies in the Clinical Practice. The Finding BRCANess Project

Conditions
-----------------
Ovarian Neoplasms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with advanced epithelial ovarian cancer (stage IC or higher). Exclusion Criteria: Non
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with a genetic profile defined by sequencing that could predict Progression Free Survival (PFS) | Clinical data from the enrolled patients will be recorded and related to the results obtained from sequencing the DNA isolated from tumor samples. Whole exome sequencing (WES) will be used for sequencing DNA isolated from paraffin embedded samples and Whole genome association study (GWAS) for the DNA from frozen samples. The bioinformatics analysis of the sequencing results will allow us to identify altered regions and affected genes and the minimal common regions of imbalance. All detected mutations will be confirmed by Sanger sequencing to ensure the reliability of the findings. | 1 year |
Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis

Study Overview
=================
Brief Summary
-----------------
This study measures the proportion of enrolled patients taking the uninterrupted HIV post-exposure prophylaxis Genvoya for four weeks

Detailed Description
-----------------
This study measures the proportion of enrolled patients taking the uninterrupted HIV post-exposure prophylaxis Elvitegravir/Cobicistat/FTC/Tenofovir alafenamide (E/C/F/TAF) for four Weeks. Elvitegravir is an HIV-1 integrase strand transfer inhibitor (INSTI). Cobicistat is a selective, mechanism-based inhibitor of cytochrome P450 (CYP) enzymes of the CYP3A subfamily. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) and nucleoside analogue àf 2'-dexicytidine. Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor (NtRTI) and phosphonoamidate prodrug of tenofovir (2'-deoxyadenosine monophosphate analogue).

Official Title
-----------------
Evaluation of Compliance With Treatment by Elvitegravir/Cobicistat/FTC/Tenofovir Alafenamide (E/C/F/TAF) in HIV Post-exposure Prophylaxis (to Infected Blood or Sexual Contact)

Conditions
-----------------
HIV Risk

Intervention / Treatment
-----------------
* Drug: Genvoya


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: an age above 18 years consultation within 48 hours following a risk of HIV transmission (blood or sexual contact) indication for HIV post-exposure prophylaxis (according to French guidelines) person able to understand the nature of the study person who signed his consent form to participate in the study Exclusion Criteria: person exposed to HIV risk from person infected by HIV, whose therapeutic history justifies the prescription of another combination of antiretroviral drugs contraindications to the prescription of Genvoy other medical contraindications person infected by hepatitis B virus pregnant or lactating woman

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Genvoya<br>Genvoya (E/C/F/TAF) Tablet (oral use) : 150/150/200/10 mg, one tablet each day for 28 days | Drug: Genvoya<br>* Oral use (one tablet each day); 150/150/200/10 mg; 28 days<br>* Other names: (E/C/F/TAF) ATC Code: J05AR18;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients taking the uninterrupted HIV post-exposure prophylaxis for four weeks |  | Day 28 |
Exploring the Relationship Between Varying CO2 Levels and the Regional BOLD Signal, by Using Breathing Exercises

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to explore how arterial PaCO2 effect regional Blood Oxygen Level Dependent (BOLD) signal, and indirectly the brain regional O2 level .

Detailed Description
-----------------
Among many parameters effecting cerebral blood flow(CBF), partial pressure of CO2 (PaCO2) in arterial blood has a significant effect. A small increase in arterial PaCO2 level will cause a significant increase of CBF , followed by increase of O2 level . The main objective is to explore the effect of arterial PaCO2 level on regional CBF and brain O2 level, by using breathing exercises to modulate arterial PaCO2. The regional Blood Oxygen Level Dependent (BOLD) signal produced by MRI , will indicate the regional O2 level.

Official Title
-----------------
Exploring the Relationship Between Varying CO2 Levels and the Regional BOLD Signal, by Using Breathing Exercises .

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adults over 18 years old . Exclusion Criteria: under 18 years old. Artificial pacemaker implantable cardioverter-defibrillator (ICD) Hearing aid, implantable or portable. artificial heart valve Surgical clips Metal fragments in eyes Electronic stimulators Implanted pumps Implantable Neurostimulation Device metal fragments of any sort Permanent makeup or tattoo transfusion pump pregnant or breast feeding women False teeth , retainer or dental crown

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A18<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Regional BOLD signal dependency on arterial PaCO2., Effect of breathing exercises on brain regional O2 level., Healthy subjects